<DOC>
	<DOCNO>NCT00083577</DOCNO>
	<brief_summary>The purpose research study helpful thalidomide control myeloma disease study side effect result thalidomide .</brief_summary>
	<brief_title>Anti-Angiogenesis Therapy Using Thalidomide Multiple Myeloma</brief_title>
	<detailed_description>Patients receive thalidomide oral form ( mouth ) . Then dose thalidomide increase week week 7 long significant side effect . After week 7 , patient continue receive thalidomide long toxicity require treatment stop long evidence rapid tumor growth treatment thalidomide . Routine physical examination blood test do monitor effect treatment toxicity encounter , , provide available treatment side effect accordingly . Blood test do month first six month receive thalidomide .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>All patient must confirm diagnosis previously treat , active multiple myeloma Myeloma protein evident evaluate response Must 18 year age old . Women childbearing age fertile men must use medically acceptable mean birth control study 6 month thereafter . Patients must sign informed consent participate study , fully aware know teratogenic potential drug Patients must total white blood cell count 2,000 K/microliters . Patients may anemic thrombocytopenic provide felt due extensive marrow involvement myeloma Patients must adequate liver function demonstrate direct bilirubin &lt; = 2.0 mg/dL . Patients must active infection require parenteral antibiotic No concurrent therapy myeloma permit Thalidomide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Thalidomide</keyword>
	<keyword>Anti-Angiogenesis</keyword>
</DOC>